Rallybio Corp

For the period ended Jun 30, 2025. Filed Aug 7, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 7, 2025

RLYB$15.76+0.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss

Condensed Consolidated Statements of Operations and Comprehensive Loss

	FOR THE THREE MONTHS ENDED JUNE 30,		FOR THE SIX MONTHS ENDED JUNE 30,
(in thousands, except share and per share amounts)	2025	2024	2025	2024
Revenue:
Collaboration and license revenue	$212	$299	$424	$299
Total revenue	212	299	424	299
Operating expenses:
Research and development	6,074	12,946	11,799	25,882
General and administrative	4,195	4,388	8,352	11,239
Total operating expenses	10,269	17,334	20,151	37,121
Loss from operations	(10,057)	(17,035)	(19,727)	(36,822)
Other income:
Interest income	523	1,143	1,167	2,419
Other income	118	143	292	310
Total other income, net	641	1,286	1,459	2,729
Loss before equity in losses of joint venture	(9,416)	(15,749)	(18,268)	(34,093)
Loss on investment in joint venture	287	487	874	1,172
Net loss	$(9,703)	$(16,236)	$(19,142)	$(35,265)
Net loss per common share, basic and diluted	$(0.22)	$(0.37)	$(0.43)	$(0.83)
Weighted-average common shares outstanding, basic and diluted	44,841,140	44,128,059	44,808,055	42,450,837
Other comprehensive loss:
Net unrealized loss on marketable securities	(30)	—	(51)	(86)
Other comprehensive loss	(30)	—	(51)	(86)
Comprehensive loss	$(9,733)	$(16,236)	$(19,193)	$(35,351)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.